Lets see if analysts are bullish or bearish on these popular shares. The post Buy, hold, sell: CBA, CSL, and DroneShield ...

Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

Dr. Nick Ioannou brings decades of academia, industry, and clinical experience in organ transplant, nephrology, cardiology, ...

Anemia and transfusion of red blood cells are common in patients undergoing valve surgery for infective endocarditis, and ...

CSL Ltd (ASX: CSL) shares slumped in 2025, but the outlook may be improving. Here’s why I think CSL could beat the ASX 200 ...

CSL Ltd (ASX: CSL) shares were sold off in 2025. Let's find out why and see if this is a buying opportunity for ...

It has been almost two years since the first steps were taken toward new rules to allow men who have sex with men to donate ...

Drs Harrington and Gibson’s annual review of cardiovascular medicine: ACS guidelines, antiplatelet management, GLP-1s, and ...

Here's why things could be better next year. The post I think these ASX blue chips shares are primed for a major rebound in 2026 appeared first on The Motley Fool Australia.

A report from the Australian National Audit Office into the ­Seqirus deal – and a separate agreement with US pharmaceutical company Moderna for an mRNA vaccine factory – argues the government strayed ...

Accusing CSL of a “disgraceful” approach to bargaining, the CSL Behring workers are taking the protected action as the company puts out a revised offer to workers following the voting down of a ...

Health editor Michael Smith on CSL’s remarkable story, why investors have fallen out of love with the healthcare giant and what Trump has to do with it. CSL was run like a bureaucracy until 1990 when ...